Abstract
While many patients with early stage kidney cancer can be cured by removal of the tumor and kidney ('nephrectomy'), upward of 40% of patients can recur due to microscopic spread of the cancer prior to surgery. Adding anticancer drugs that are effective in the metastatic setting to surgery has potential to eliminate the microscopic disease and increase cure rates. The PROSPER renal cell carcinoma study is testing whether adding nivolumab, a drug that engages the immune system to better recognize, fight and eliminate the cancer, will improve disease control over surgery alone. Nivolumab will be given before and after surgery to see if it reduces the chance of the disease returning and decreases death from kidney cancer compared with patients receiving surgery only.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1683-1695 |
| Number of pages | 13 |
| Journal | Future Oncology |
| Volume | 15 |
| Issue number | 15 |
| DOIs | |
| State | Published - May 2019 |
Funding
The study is coordinated by the ECOG-ACRIN Cancer Research Group and supported by the National Cancer Institute. The study drug is provided by the Bristol-Myers Squibb under a Cooperative Research and Development Agreement with the National Cancer Institute. A Kapoor had research funding from Pfizer Oncology, Novartis Oncology, BMS and Roche. CG Drake is an advisor/consultant for BMS, Compugen, Roche/Genentech, Regeneron, AZ Medimmune and Merck; and a co-inventor on patents licensed from Johns Hopkins to AZ/Medimmune and to BMS. DYC Heng is an advisor for BMS, Pfizer, Novartis and Exelixis. PN Lara is a consultant for BMS. TK Choueiri has research funding from AstraZeneca, Bayer, BMS, Cerulean, Eisai, Foundation Medicine, Inc., Exelixis, Ipsen, Tracon, Genentech, Roche, Roche Products Limited, GlaxoSmithKline, Merck, Novartis, Peloton, Pfizer, Prometheus Labs, Corvus, Calithera, Analysis Group and Takeda; is a consultant/advisor to AstraZeneca, Alexion, Sanofi/Aventis, Bayer, BMS, Cerulean, Eisai, Foundation Medicine, Inc., Exelixis, Genentech, Heron Therapeutics, Roche, GlaxoSmithKline, Merck, Novartis, Peloton, Pfizer, EMD Serono, Prometheus Labs, Corvus, Ipsen, Up-to-Date, NCCN and Analysis Group; and has received honoraria from AstraZeneca, Alexion, Sanofi/Aventis, Bayer, BMS, Cerulean, Eisai, Foundation Medicine, Inc., Exelixis, Genentech, Roche, GlaxoSmithKline, Merck, Novartis, Peloton, Pfizer, EMD Serono, Prometheus Labs, Corvus, Ipsen, Up-to-Date, NCCN, Analysis Group, NCCN, Michael J. Hennessy (MJH) Associates, Inc. (Healthcare Communications Company with several brands such as OnClive and PER), L-path, Kidney Cancer Journal, Clinical Care Options, Platform Q, Navinata Healthcare, Harborside Press, American Society of Medical Oncology, NEJM, Lancet Oncology and Heron Therapeutics. EA Singer has received research support from Astellas/Medivation, grant from the National Cancer Institute (P30CA072720). WM Stadler is a consultant for Astra-Zeneca, Bayer, BMS, Caremark/CVS, Clovis, Eisai, Genentech, Pfizer, research support (to institution): AbbVie, Astra-Zeneca, Bayer, Bristol-Myers-Squibb, Boehringer-Ingelheim, Calithera, Eisai, Exelixis, Genentech (Roche), Merck, Novartis, Pfizer, Tesaro, X4Pharmaceuticals; and has held miscellaneous/editorial roles for Cancer (ACS) and Up-To-Date. S Signoretti has received research support (to institution) from Exelixis, AstraZeneca, Bristol-Myers Squibb consultant: Merck, AstraZeneca/MedImmune, Verastem, American Association for Cancer Research and National Cancer Institute; and receives royalties for CDX2 antibody from BioGenex Laboratories. RT Gupta is a consultant for Bayer Pharma AG, Invivo Corp., and Bard; and is also on the speakers bureau for Bayer Pharma AG. MD Michaelson is an advisor for Pfizer, Novartis and Exelixis. DF McDermott is a consultant for Kidney Cancer Research: BMS, Pfizer, Merck, Novartis, Eisai, Exelixis, Array BioPharm and Genentech BioOncology; and has received research support from Kidney Cancer Research: Prometheus. D Cella is a consultant for Bristol-Myers Squibb, Bayer, Pfizer, Novartis, Aveo, Exelixis and Merck; and has received research support (to institution) from Bristol-Myers Squibb, Bayer, Pfizer, Novartis and GlaxoSmithKline. LI Wagner is a consultant for Celgene Inc. and Connect Myeloma registry. NB Haas is an advisor for Exelixis and Novartis. MA Carducci is an advisor for Astellas, Pfizer, Roche/Genentech, Merck, AbbVie; and has received research support (to institution) from Astra Zeneca, EMD Serrano, Pfizer, Bristol-Myers Squibb and Gilead. LC Harshman is an advisor for Bayer, Genentech, Dendreon, Pfizer, Medivation/Astellas, Kew Group, Theragene, Corvus, Merck, Exelixis; Novartis and Jounce; and has received research support (to institution) from Bayer, Sotio, Bristol-Myers Squib, Merck, Takeda, Dendreon/Valeant, Janssen, Medivation/Astellas, Genentech and Pfizer. ME Allaf has received research support from Progenics and is NIH funded (grant number: U10CA180820). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript.
Keywords
- PROSPER RCC
- clinical trial
- kidney cancer
- neoadjuvant therapy
- nephrectomy
- nivolumab
- perioperative
- presurgical
- renal cell carcinoma
ASJC Scopus subject areas
- Oncology
- Cancer Research
